Literature DB >> 22093601

Role of dialysis technology in the removal of uremic toxins.

Andrew Davenport1.   

Abstract

Traditionally, the amount of hemodialysis prescribed for a patient has been based on urea clearance, as urea is not only retained in patients with chronic kidney disease, but also readily measurable, by reliable and inexpensive assays. More recently, other retained solutes, phosphate, β2 microglobulin, and latterly p-cresol have been reported to be associated with increased risk of mortality in hemodialysis patients. As such, developments in dialysis practice that would result in greater clearance of water-soluble middle-sized toxins and also protein-bound and/or organic solutes are being studied. Although session time is a key factor, switching from low flux to dialyzers with larger pores, the addition of convective transport with hemodiafiltration can help increase phosphate and β2 microglobulin clearances. Adsorption techniques can increase the clearance of organic and protein bound toxins either directly or indirectly by regenerating dialysate and ultrafiltrates. 2011 The Author; Hemodialysis International. 2011 International Society for Hemodialysis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22093601     DOI: 10.1111/j.1542-4758.2011.00602.x

Source DB:  PubMed          Journal:  Hemodial Int        ISSN: 1492-7535            Impact factor:   1.812


  7 in total

1.  Plasma p-cresol lowering effect of sevelamer in non-dialysis CKD patients: evidence from a randomized controlled trial.

Authors:  Eleonora Riccio; Massimo Sabbatini; Dario Bruzzese; Lucia Grumetto; Cristina Marchetiello; Maria Amicone; Michele Andreucci; Bruna Guida; Davide Passaretti; Giacomo Russo; Antonio Pisani
Journal:  Clin Exp Nephrol       Date:  2017-11-20       Impact factor: 2.801

Review 2.  Regression of vascular calcification in chronic kidney disease - feasible or fantasy? a review of the clinical evidence.

Authors:  Oscar Leonard; Jonas Spaak; David Goldsmith
Journal:  Br J Clin Pharmacol       Date:  2013-10       Impact factor: 4.335

3.  Plasma p-cresol lowering effect of sevelamer in peritoneal dialysis patients: evidence from a Cross-Sectional Observational Study.

Authors:  Bruna Guida; Mauro Cataldi; Eleonora Riccio; Lucia Grumetto; Andrea Pota; Silvio Borrelli; Andrea Memoli; Francesco Barbato; Gennaro Argentino; Giuliana Salerno; Bruno Memoli
Journal:  PLoS One       Date:  2013-08-28       Impact factor: 3.240

Review 4.  Portable and wearable dialysis devices for the treatment of patients with end-stage kidney failure: Wishful thinking or just over the horizon?

Authors:  Andrew Davenport
Journal:  Pediatr Nephrol       Date:  2014-10-21       Impact factor: 3.714

5.  Benefits and harms of high-dose haemodiafiltration versus high-flux haemodialysis: the comparison of high-dose haemodiafiltration with high-flux haemodialysis (CONVINCE) trial protocol.

Authors:  Peter J Blankestijn; Kathrin I Fischer; Claudia Barth; Krister Cromm; Bernard Canaud; Andrew Davenport; Diederick E Grobbee; Jörgen Hegbrant; Kit C Roes; Matthias Rose; Giovanni Fm Strippoli; Robin Wm Vernooij; Mark Woodward; G Ardine de Wit; Michiel L Bots
Journal:  BMJ Open       Date:  2020-02-05       Impact factor: 2.692

6.  Plasma concentrations of the vasoactive peptide fragments mid-regional pro-adrenomedullin, C-terminal pro-endothelin 1 and copeptin in hemodialysis patients: associated factors and prediction of mortality.

Authors:  Ferruh Artunc; Albina Nowak; Christian Mueller; Tobias Breidthardt; Raphael Twerenbold; Robert Wagner; Andreas Peter; Hans-Ulrich Haering; Stefan Ebmeyer; Bjoern Friedrich
Journal:  PLoS One       Date:  2014-01-22       Impact factor: 3.240

Review 7.  Hemodialysis-Nutritional Flaws in Diagnosis and Prescriptions. Could Amino Acid Losses be the Sharpest "Sword of Damocles"?

Authors:  Piergiorgio Bolasco
Journal:  Nutrients       Date:  2020-06-14       Impact factor: 5.717

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.